Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Capital Expenditures (2022 - 2025)

Historic Capital Expenditures for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $195000.0.

  • Century Therapeutics' Capital Expenditures changed N/A to $195000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year change of. This contributed to the annual value of $154000.0 for FY2024, which is 9887.89% down from last year.
  • As of Q3 2025, Century Therapeutics' Capital Expenditures stood at $195000.0.
  • Century Therapeutics' Capital Expenditures' 5-year high stood at $10.5 million during Q2 2022, with a 5-year trough of $195000.0 in Q3 2025.
  • For the 4-year period, Century Therapeutics' Capital Expenditures averaged around $3.5 million, with its median value being $3.3 million (2023).
  • As far as peak fluctuations go, Century Therapeutics' Capital Expenditures surged by 2271.94% in 2023, and later crashed by 9411.11% in 2024.
  • Quarter analysis of 4 years shows Century Therapeutics' Capital Expenditures stood at $6.3 million in 2022, then plummeted by 84.37% to $980000.0 in 2023, then crashed by 72.96% to $265000.0 in 2024, then fell by 26.42% to $195000.0 in 2025.
  • Its last three reported values are $195000.0 in Q3 2025, $317000.0 for Q2 2025, and $475000.0 during Q1 2025.